Literature DB >> 20211686

Isolation and characterization of novel pituitary tumor related genes: a cDNA representational difference approach.

Xun Zhang1, Yunli Zhou, Anne Klibanski.   

Abstract

Recently, progress has been made in understanding human pituitary tumor pathogenesis by the investigation of differences in gene expression between normal pituitary tissue and pituitary tumors. A number of approaches, including differential display (DD), representational difference analysis (RDA), and microarray analysis have been used and several molecular targets potentially associated with pituitary tumor development and invasion have been identified. We have used RDA to compare gene expression patterns between normal human pituitary and clinically non-functioning pituitary adenomas, and identified genes with growth suppression function which are expressed in the normal pituitary but not in pituitary tumors. In particular, we have focused on an imprinted gene, Maternally Expressed Gene 3 (MEG3), which is specifically associated with clinically non-functioning pituitary adenomas of a gonadotroph lineage. MEG3 functions to suppress tumor cell growth, increase protein expression of the tumor suppressor p53, and selectively activate p53 target genes. Interestingly, MEG3 does not encode a protein but a non-coding RNA. Therefore, these studies have revealed novel mechanisms for the function of a non-coding RNA in pituitary physiology and tumorigenesis. 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20211686      PMCID: PMC2904873          DOI: 10.1016/j.mce.2010.02.040

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  83 in total

1.  Subtractive hybridization.

Authors:  Jörg H W Distler; Oliver Distler; Michel Neidhart; Steffen Gay
Journal:  Methods Mol Med       Date:  2007

2.  Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas.

Authors:  X Zhang; G A Horwitz; A P Heaney; M Nakashima; T R Prezant; M D Bronstein; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  1999-02       Impact factor: 5.958

3.  Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia.

Authors:  Xuegong Zhu; Sylvia L Asa; Shereen Ezzat
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

4.  Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas.

Authors:  Roger Gejman; Dalia L Batista; Ying Zhong; Yunli Zhou; Xun Zhang; Brooke Swearingen; Constantine A Stratakis; E Tessa Hedley-Whyte; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2008-07-15       Impact factor: 5.958

5.  Wnt pathway inhibitors are strongly down-regulated in pituitary tumors.

Authors:  Marianne S Elston; Anthony J Gill; John V Conaglen; Adele Clarkson; Janet M Shaw; Andrew J J Law; Raymond J Cook; Nicholas S Little; Roderick J Clifton-Bligh; Bruce G Robinson; Kerrie L McDonald
Journal:  Endocrinology       Date:  2007-12-13       Impact factor: 4.736

6.  AIP Mutations are not identified in patients with sporadic pituitary adenomas.

Authors:  Rebecca DiGiovanni; Stefano Serra; Shereen Ezzat; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

7.  The H19 locus acts in vivo as a tumor suppressor.

Authors:  Tomomi Yoshimizu; Audrey Miroglio; Marie-Anne Ripoche; Anne Gabory; Maria Vernucci; Andrea Riccio; Sabine Colnot; Cécile Godard; Benoit Terris; Hélène Jammes; Luisa Dandolo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-21       Impact factor: 11.205

8.  Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk.

Authors:  Atsushi Kaneda; Chiaochun J Wang; Raymond Cheong; Winston Timp; Patrick Onyango; Bo Wen; Christine A Iacobuzio-Donahue; Rolf Ohlsson; Rita Andraos; Mark A Pearson; Alexei A Sharov; Dan L Longo; Minoru S H Ko; Andre Levchenko; Andrew P Feinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-17       Impact factor: 11.205

9.  Expression of p16(INK4A) gene in human pituitary tumours.

Authors:  Gloria Machiavelli; Javier Cotignola; Karina Danilowicz; Carolina Carbonara; Andrea Paes de Lima; Armando Basso; Oscar Domingo Bruno; Irene Szijan
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

10.  Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumor.

Authors:  Richard H Scott; Jenny Douglas; Linda Baskcomb; Nikki Huxter; Karen Barker; Sandra Hanks; Alan Craft; Mary Gerrard; Janice A Kohler; Gill A Levitt; Sue Picton; Barry Pizer; Milind D Ronghe; Denise Williams; Jackie A Cook; Pascal Pujol; Eamonn R Maher; Jillian M Birch; Charles A Stiller; Kathy Pritchard-Jones; Nazneen Rahman
Journal:  Nat Genet       Date:  2008-10-05       Impact factor: 38.330

View more
  10 in total

Review 1.  Molecular function and regulation of long non-coding RNAs: paradigms with potential roles in cancer.

Authors:  Mohammadreza Hajjari; Atefeh Khoshnevisan; Young Kee Shin
Journal:  Tumour Biol       Date:  2014-09-30

2.  Long Noncoding RNA MEG3 Is an Epigenetic Determinant of Oncogenic Signaling in Functional Pancreatic Neuroendocrine Tumor Cells.

Authors:  Sucharitha Iyer; Sita D Modali; Sunita K Agarwal
Journal:  Mol Cell Biol       Date:  2017-10-27       Impact factor: 4.272

3.  Lateral ventricle injection of orexin-A ameliorates central precocious puberty in rat via inhibiting the expression of MEG3.

Authors:  Yue-Hong Tao; Nazir Sharif; Bi-He Zeng; Yan-Yan Cai; Yu-Xiu Guo
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

4.  Expression of cell growth negative regulators MEG3 and GADD45γ is lost in most sporadic human pituitary adenomas.

Authors:  Lisiane Cervieri Mezzomo; Paulo Henrique Gonzales; Frederico Giacomoni Pesce; Nélson Kretzmann Filho; Nelson Pires Ferreira; Miriam Costa Oliveira; Maria Beatriz Fonte Kohek
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

Review 5.  MEG3: a novel long noncoding potentially tumour-suppressing RNA in meningiomas.

Authors:  Vladimir Balik; Josef Srovnal; Igor Sulla; Ondrej Kalita; Tatiana Foltanova; Miroslav Vaverka; Lumir Hrabalek; Marian Hajduch
Journal:  J Neurooncol       Date:  2013-01-11       Impact factor: 4.130

6.  The Beginning of the Road for Non-Coding RNAs in Normal Hematopoiesis and Hematologic Malignancies.

Authors:  Elisabeth F Heuston; Kenya T Lemon; Robert J Arceci
Journal:  Front Genet       Date:  2011-12-28       Impact factor: 4.599

7.  Concomitant downregulation of the imprinted genes DLK1 and MEG3 at 14q32.2 by epigenetic mechanisms in urothelial carcinoma.

Authors:  Annemarie Greife; Judith Knievel; Teodora Ribarska; Günter Niegisch; Wolfgang A Schulz
Journal:  Clin Epigenetics       Date:  2014-11-23       Impact factor: 6.551

Review 8.  The molecular pathogenesis of pituitary adenomas: an update.

Authors:  Xiaobing Jiang; Xun Zhang
Journal:  Endocrinol Metab (Seoul)       Date:  2013-12

Review 9.  Dysregulated expression of long noncoding RNAs in gynecologic cancers.

Authors:  Elahe Seyed Hosseini; Matthieu Meryet-Figuiere; Hamed Sabzalipoor; Hamed Haddad Kashani; Hossein Nikzad; Zatollah Asemi
Journal:  Mol Cancer       Date:  2017-06-21       Impact factor: 27.401

10.  The long non-coding RNA Meg3 is dispensable for hematopoietic stem cells.

Authors:  Pia Sommerkamp; Simon Renders; Luisa Ladel; Agnes Hotz-Wagenblatt; Katharina Schönberger; Petra Zeisberger; Adriana Przybylla; Markus Sohn; Yunli Zhou; Anne Klibanski; Nina Cabezas-Wallscheid; Andreas Trumpp
Journal:  Sci Rep       Date:  2019-02-14       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.